ZM-241,385

Last updated

ZM-241,385
ZM-241,385 Structure.svg
Names
Preferred IUPAC name
4-(2-{[7-Amino-2-(furan-2-yl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino}ethyl)phenol
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.216.533 OOjs UI icon edit-ltr-progressive.svg
PubChem CID
UNII
  • InChI=1S/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22) X mark.svgN
    Key: PWTBZOIUWZOPFT-UHFFFAOYSA-N X mark.svgN
  • InChI=1/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22)
    Key: PWTBZOIUWZOPFT-UHFFFAOYAJ
  • Oc1ccc(CCNc2nc3nc(c4ccco4)nn3c(N)n2)cc1
Properties
C16H15N7O2
Molar mass 337.343 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

ZM-241,385 is a high affinity antagonist ligand selective for the adenosine A2A receptor. [1]

In animal models, ZM-241,385 has been shown to protect against beta amyloid neurotoxicity and therefore may be useful as a treatment for Alzheimer's disease. [2] ZM-241,385 has also been shown to enhance L-DOPA derived dopamine release and therefore may be useful in the treatment of Parkinson's disease. [3]

References

  1. ↑ Palmer TM, Poucher SM, Jacobson KA, Stiles GL (December 1995). "125I-4-(2-(7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5) triazin-5-yl-amino)ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor". Molecular Pharmacology. 48 (6): 970–4. PMC   3479638 . PMID   8848012. Archived from the original on 2008-09-07. Retrieved 2008-10-15.
  2. ↑ Dall'Igna OP, Porciúncula LO, Souza DO, Cunha RA, Lara DR, Dall'lgna OP (April 2003). "Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity". British Journal of Pharmacology . 138 (7): 1207–9. doi:10.1038/sj.bjp.0705185. PMC   1573785 . PMID   12711619.
  3. ↑ Gołembiowska K, Dziubina A (September 2004). "Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats". Neuropharmacology. 47 (3): 414–26. doi:10.1016/j.neuropharm.2004.04.018. PMID   15275831. S2CID   13484028.

ZM+241385 at the U.S. National Library of Medicine Medical Subject Headings (MeSH)


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.